Defilade Capital Management L.P. Boosts Position in Elanco Animal Health Incorporated $ELAN

Defilade Capital Management L.P. increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 132.0% during the 1st quarter, HoldingsChannel reports. The fund owned 931,121 shares of the company’s stock after acquiring an additional 529,838 shares during the quarter. Elanco Animal Health comprises approximately 3.1% of Defilade Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Defilade Capital Management L.P.’s holdings in Elanco Animal Health were worth $22,282,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ELAN. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the last quarter. Root Financial Partners LLC boosted its holdings in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the 4th quarter valued at about $41,000. Torren Management LLC purchased a new stake in shares of Elanco Animal Health in the 4th quarter valued at approximately $46,000. Finally, Bessemer Group Inc. grew its stake in shares of Elanco Animal Health by 33.2% in the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock valued at $50,000 after buying an additional 525 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling

In other news, insider Rajeev A. Modi purchased 4,911 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the stock in a transaction dated Friday, May 15th. The shares were purchased at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ELAN. JPMorgan Chase & Co. raised their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Morgan Stanley upped their price objective on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. TD Cowen lifted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Finally, Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $28.73.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $26.42 on Monday. The company’s 50 day simple moving average is $24.55 and its 200-day simple moving average is $24.07. The company has a market capitalization of $13.20 billion, a price-to-earnings ratio of -52.85, a price-to-earnings-growth ratio of 1.72 and a beta of 1.68. Elanco Animal Health Incorporated has a 1 year low of $13.39 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.